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Objective: The treatment of Acute Myeloid Leukemia (AML) leads to several functional limitations. Especially cardiac
burden following cardiotoxic chemotherapy, which limits exercise and competitive sport in the long-term survivors.
Subject and methods: We report on a young female amateur triathlete born in 1997, who was diagnosed with
AML at the age of fifteen. She had chemotherapy with a cumulative dose of about 1000 mg/m2 anthracyclines
and allogeneic stem cell transplantation which was successful, but she suffered from cardiotoxic systolic heart
failure with a left ventricular ejection fraction (LVEF) <55 % and an impaired peak oxygen uptake of 23.2 ml/min/kg and
53 % of predicted, respectively. After medical examination and counselling with a sport scientist she started a tailored
training of aerobic exercise. She was evaluated at regular intervals which resulted in increasing the training load
and volume. Eventually her training hours was stepwise increased to 12 h training per week, which includes high
intensity intervals.
Results: Within almost 3 years, her exercise performance improved tremendously. Workload doubled from 2.1 W/kg
to 4.2 W/kg, peak oxygen uptake increased from 23.2 ml/min/kg to 49.1 ml/min/kg and from 53 to 135 %,
respectively. Moreover, she participated in several competitions. However, LVEF remains almost unchanged.
Conclusion: With the right training and under medical surveillance competitive exercise with an anthracycline-damaged
heart is still achievable. Moreover, competitive training and exercise seems to be safe and feasible.
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Treatment of “Acute Myeloid Leukemia” (AML) in-
cludes chemotherapy with anthracyclines, whose cardio-
toxicity is well documented in cancer literature [1].
Higher doses of anthracyclines (>250 mg/m2) are directly
associated with an exponentially higher risk of developing
cardiac pathogenesis [2, 3]. Moreover, anthracycline leads
to cardiac complications like cardiomyopathy, reduced left
ventricular ejection fraction (<55 %) and higher arterial
stiffness in 16 % of all AML-long-term-survivors [1, 4, 5].
Since children and young adults tend to suffer from this* Correspondence: j.mueller@tum.de
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come of every single survivor has to be taken into account.
Contemporary, curative treatment of chemotherapeu-
tic protocols, like AFM-BFM1, reduce the dosage of car-
diotoxic anthracycline by replacing Idarubicin by L-DNR
for less treatment-related mortality [6, 7]. However,
studies support that also low doses of anthracyclines are
still cardiotoxic [8]. Impaired cardiac response to exer-
cise and reduced exercise capacity is frequently seen in
cancer survivors treated with cardiotoxic drugs [9]. For
that reason tailored exercise recommendations should
be given to those patients to improve or even normalize
exercise capacity [9].
Even though recent studies demonstrate comparable ex-
ercise capacity of adolescent cancer survivors and healthy
controls [9] there are still many patients that suffer fromle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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competitive athlete’s after cancer therapy is still lacking.
Case report
We report on a female amateur triathlete born in 1997 who
is suffering from AML diagnosed in September 2011 at the
age of 15. She received the AML-BFM 2004 chemotherapy
protocol with liposomal Daunorubicin, Mitoxantron and
Idarubicin as cardiotoxic anthracyclines and further allo-
geneic bone marrow transplantation in January 2012. Her
therapeutic regime contains a dose about 750 mg per
square meter body surface anthracyclines, summarized to
her bodily parameters at that time multiplied with 1,43 m2
(cumulative dose of all given protocols: 1.072,5 mg).
Her medication nowadays consists of diuretics, Beta
blocker, ACE-inhibitor and an additional hormone
therapy2. No relapse was found since then.
In December 2012, she received her first echocardiog-
raphy and the cardiopulmonary exercise test (CPET) on
electronic braked bicycle ergometer at our institution.
Echocardiography revealed limited contractility of the
normal sizes left ventricle (Ejection fraction 50–55 %).
Exercise capacity was severely reduced with a peak VO2
of 23.3 ml/min/kg and peak workload of 88 W and 2.07Fig. 1 Cardiac response to exercise from cardiopulmonary exercise testing.
Acute Myeloid Leukemia showed a drop in systolic blood pressure through
(b). Four years after therapy for Acute Myeloid Leukemia and continuous c
pressure (c), oxygen and heart rate response to exercise (d)W/kg, respectively. Especially the cardiac panels from
the nine panel plot derived from CPET revealed a lim-
ited cardiac response to exercise (Fig. 1).
Afterwards we (athlete, sport scientist, medical doctors
and parents), designed a training schedule with her coach
including swimming, walking and cycling starting with
just aerobic intensities. Re-evaluation was performed ap-
proximately every 6 month with the same procedures,
training was adjusts, intensity and duration was progres-
sively increased up to 12–14 h a week. Over the past three
years exercise capacity increased tremendously to a peak
VO2 of 49.1 ml/min/kg and peak workload of 224 W and
4.23 W/kg, respectively (Fig. 1 and Table 1). Her final
CPET showed a perfect cardiac response to exercise with a
well increasing VO2, heart rate and systolic blood pressure
during exercise. She also competed in sprint triathlons.
In contrast her cardiac function derived from echocar-
diography shows only a slight improvement in contract-
ility (Ejection fraction 55–60 %).
Discussion
Leisure-time physical activity is associated with reduced
cancer incidence [11] and exercise interventions in adult’s
cancer patients also provide positive results [12, 13]. AlsoFirst cardiopulmonary exercise test almost one year after therapy for
out exercise (a) and limitations in oxygen uptake (a) and heart rate
ompetitive exercise training showing a tremendous improved blood
Table 1 Measures from cardiopulmonary exercise testing
06.12.2012 06.06.2013 26.09.2013 27.03.2014 11.11.2014 29.07.2015
Resting Heart rate (beats per minute) 95 98 79 71 86 93
Peak Heart rate (beats per minute) 173 179 179 190 190 187
Resting Blood Pressure (mmHg) 100/72 85/65 99/62 93/63 83/57 110/62
Peak Blood Pressure (mmHg) 93/58 - 113/68 136/80 120/66 147/74
Peak oxygen uptake (ml/min/kg) 23.2 28.8 32.4 35.7 40.2 49.1
Peak oxygen uptake (% predicted) 53 78 82 91 107 135
Workload (Watt/kg) 2.07 2.68 3.02 3.88 3.92 4.23
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well documented in adults, but can be questionable, eg in
the professional bicyclist Lance Armstrong.
The evidence for benefits in children is rather low. De-
creased physical fitness and activity is reported in child-
hood cancer survivors. Unfortunately, exercise intervention
studies in childhood cancer survivors were of moderate to
very low quality [14].
The recent case also demonstrates a well-performed
re-entry after leukemia into competitive sport, to the
contrary of the majority of mostly sedentary pediatric
leukemia patients [15]. Not only fighting cancer suc-
cessfully, our individual developed tremendous im-
provements in terms of body condition and her
cardiopulmonary system after therapy. Healthy cohorts
showed a peak oxygen uptake of about 38.1 ml/min/kg,
whereas our patient had a peak oxygen uptake of
49.1 ml/min/kg (about 30 % over average) 2 years after
cancer treatment [9].
Although cardiotoxic complications were diagnosed,
she started to train with low frequencies and inten-
sities until achieving an adequate performance level
from which she intensified her training with anaerobic
content in high-intensity interval training (HIT). HIT
is a contemporary training method not only in ath-
letes but rather in cardiac rehabilitation [16]. HIT
had shown increases in skeletal muscle oxidative cap-
acity and endurance performance. More precisely that
means a higher number and size of mitochondria, less
lactate production, better utilization and energy sup-
ply during exercise and improvements in insulin sen-
sitivity. HIT drives the metabolism much harder than
regular aerobic training and adaptation in endurance
and strength occur faster. Recent studies prove the
beneficial effect of combined HIT and moderate train-
ing also for cancer patients [17, 18].
The structured training also led to further physiological
adaptations beyond the increase in peak oxygen uptake,
what substantiates findings from other investigations like
improved physical and overall health benefits, immune
cell recovery and body composition after hospitalization
and stem cell transplantation [19, 20]. Also an appropriateblood pressure rise during exercise could be restored as
well as a rise in the oxygen pulse, a surrogate for the for-
ward stroke volume (Fig. 1a in comparison to 1b).
Whereas cardiac response to exercise was extremely poor
directly after therapy, in her last CPET the increase in
blood pressure and oxygen pulse was very well regained
over the training period of 30 months in 7 CPETs. All pa-
rameters, peak oxygen uptake, oxygen pulse and blood
pressure, are predictive for survival and hospitalization in
the long-term. The improvement of all means therefore a
tremendous improvement in prognosis. This result,
achieved with a heart harmed with a high dose of cardio-
toxic anthracyclines must be seen as a pioneering success
of training after cancer treatment in an adolescent.
The outline at this point is the fact that competitive
sport after cancer therapy is possible only in alliance with
optimal medical care, close physical examinations and tai-
lored training schedules. When our patient reached adult-
hood, her body has to face the lifelong heart insufficiency
medication and possible side effects and further long-term
sequels could appear. However, due to medical and
treatment-related sequelae, especially children and young
adults have to be included in active and strengthening in-
terventions, where they keep their physical feeling already
during acute therapy [21]. Aftercare has to include wide-
spread rehabilitation, where physical exercise and an ac-
tive lifestyle has to be part of normality [22].
This case shows how cancer treatment-related toxic-
ities and long-term sequels can be accomplished by
strong will, physical capability and training effort. More-
over, it should serve as role model for all cancer survi-
vors that suffer from heart burden and other bodily
harm, whose sport and exercise was, and still is, a cen-
tral part of their life.
Endnotes
1Acute Myeloid Leukemia Berlin-Frankfurt-Münster.
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